Developing regenerative medicine technologies:

We believe that we have the most advanced clinical trial program in the stem cell field.

FDA Fast-Track clearance expedites stem cell therapy

Osiris Therapeutics, Inc. currently has two product candidates in clinical trials for a number of indications. Prochymal, an intravenously administered formulation of mesenchymal stem cells, is being evaluated in Phase 3 clinical trials for several indications, including acute graft versus host disease (GvHD) and also Crohn's disease. It is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product.

Prochymal is also being evaluated in Phase 2 clinical trials for the repair of heart tissue following a heart attack, the protection of pancreatic islet cells in patients with type 1 diabetes, and the repair of lung tissue in patients with chronic obstructive pulmonary disease.

Osiris is also evaluating Chondrogen, an injectable formulation of mesenchymal stem cells, for arthritis in the knee.

Osiris Therapeutics, Inc. • 7015 Albert Einstein Drive • Columbia, MD • 21046 • p(443) 545-1800 • osiris@osiris.comLegal Notice